

AmpliPhi Biosciences Corp  
Form SC 13G  
March 21, 2014

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934

**(Amendment No. \_\_)\***

AmpliPhi Biosciences Corporation

(Name of Issuer)

**Common Stock, par value \$0.01 per share**

(Title of Class of Securities)

**03211P103**

(CUSIP Number)

**December 16, 2013**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("**Act**") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. **03211P103 13G**

Names of Reporting Persons.  
I.R.S. Identification Nos. of above  
persons (entities only).

1.

**RA Capital Management, LLC**

Check the Appropriate Box if a

2. Member of a Group (See  
Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of

Organization **Massachusetts**

5. Sole Voting Power **0 shares**

Number of

Shares

6. Shared Voting Power **26,785,712 shares**

Beneficially

Owned by

7. Sole Dispositive Power **0 shares**

Each Reporting

Person With

8. Shared Dispositive Power **26,785,712 shares**

Aggregate Amount Beneficially Owned by Each Reporting Person

9.

**26,785,712 shares**

Check if the Aggregate Amount in Row (9) Excludes

10.

Certain Shares (See Instructions)

Percent of Class Represented by Amount in Row (9)

11.

**9.9%**

Type of Reporting Person (See Instructions)

12.

**IA**

CUSIP No. **03211P103 13G**

Names of Reporting Persons.  
I.R.S. Identification Nos.  
1. of above persons (entities only).

**Peter Kolchinsky**

Check the Appropriate Box  
2. if a Member of a Group (See Instructions)  
(a)   
(b)

3. SEC Use Only  
Citizenship or Place of

4. Organization **United States**

Number of Shares Beneficially Owned by Each Reporting Person With	5. Sole Voting Power	<b>0 shares</b>
	6. Shared Voting Power	<b>26,785,712 shares</b>
	7. Sole Dispositive Power	<b>0 shares</b>
	8. Shared Dispositive Power	<b>26,785,712 shares</b>

9. Aggregate Amount Beneficially Owned by Each Reporting Person

**26,785,712 shares**

Check if the Aggregate Amount in Row (9) Excludes

10.

Certain Shares (See Instructions)  
Percent of Class Represented by Amount in Row (9)

11.

**9.9%**

12. Type of Reporting Person (See Instructions)

**IN**

CUSIP No. **03211P103 13G**

Names of Reporting Persons.  
I.R.S. Identification Nos. of  
above persons (entities only).

1.

**RA Capital Healthcare  
Fund, L.P.**

Check the Appropriate Box if

2.a Member of a Group (See  
Instructions)

(a)

(b)

3. SEC Use Only

4. Citizenship or Place of

Organization **Delaware**

Number of Shares Beneficially Owned by Each Reporting Person With	5. Sole Voting Power	<b>0 shares</b>
	6. Shared Voting Power	<b>21,428,575 shares</b>
	7. Sole Dispositive Power	<b>0 shares</b>
	8. Shared Dispositive Power	<b>21,428,575 shares</b>

9. Aggregate Amount Beneficially Owned by Each Reporting Person

**21,428,575 shares**

Check if the Aggregate Amount in Row (9) Excludes

10.

Certain Shares (See Instructions)

Percent of Class Represented by Amount in Row (9)

11.

**7.9%**

Type of Reporting Person (See Instructions)

12.

**PN (Limited Partnership)**

CUSIP No. **03211P103**

**Item 1.**

(a) **Name of Issuer:** AmpliPhi Biosciences Corporation (the “Issuer”).

(b) **Address of the Issuer’s Principal Executive Offices:** 4870 Sadler Road, Suite 300, Glen Allen, Virginia, 23060.

**Item 2.**

(a) **Name of Person Filing:** This joint statement on Schedule 13G is being filed by Peter Kolchinsky, RA Capital Management, LLC (“Capital”), and RA Capital Healthcare Fund, L.P. (the “Fund”). Mr. Kolchinsky, Capital and the Fund are collectively referred to herein as the “Reporting Persons.”

(b) **Address of Principal Business Office:** The principal business office of the Reporting Persons is c/o RA Capital Management, LLC, 20 Park Plaza, Suite 1200, Boston, MA 02116.

(c) **Citizenship:** Capital is a Massachusetts limited liability company. The Fund is a Delaware limited partnership. Mr. Kolchinsky is a United States citizen.

(d) **Title and Class of Securities:** Common stock (“Common Stock”).

(e) **CUSIP Number:** 03211P103

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

Not applicable.

**Item 4. Ownership:**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned:\*\*

RA Capital Management, LLC – 26,785,712 shares

Peter Kolchinsky – 26,785,712 shares

RA Capital Healthcare Fund, L.P. – 21,428,575 shares

(b) Percent of Class:\*\*

RA Capital Management, LLC – 9.9%

Peter Kolchinsky – 9.9%

RA Capital Healthcare Fund, L.P. – 7.9%



CUSIP No. **03211P103**

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote \*\*

RA Capital Management, LLC - 0 shares

Peter Kolchinsky - 0 shares

RA Capital Healthcare Fund, L.P. - 0 shares

(ii) shared power to vote or to direct the vote\*\*

RA Capital Management, LLC – 26,785,712 shares

Peter Kolchinsky – 26,785,712 shares

RA Capital Healthcare Fund, L.P. – 21,428,575 shares

(iii) sole power to dispose or to direct the disposition of\*\*

RA Capital Management, LLC - 0 shares

Peter Kolchinsky - 0 shares

RA Capital Healthcare Fund, L.P. - 0 shares

(iv) shared power to dispose or to direct the disposition of\*\*

RA Capital Management, LLC – 26,785,712 shares

Peter Kolchinsky – 26,785,712 shares

RA Capital Healthcare Fund, L.P. – 21,428,575 shares

\*\* Shares reported herein for the Reporting Persons represent shares of Common Stock issuable upon the conversion of certain shares of Series B Convertible Preferred Stock (“Series B Shares”) and shares of Common Stock the Reporting Persons have the right to acquire through the exercise of warrants dated June 26, 2013 (“Warrant Shares”) beneficially owned as set forth below. In the aggregate, the Reporting Persons own 2,142,857 Series B Shares convertible into 21,428,570 shares of Common Stock and 5,357,142 Warrant Shares. The Series B Shares and Warrant Shares may not be converted such that the number of shares of Common Stock held by the Reporting Persons and their affiliates after such conversion exceeds 9.99% of the outstanding shares of Common Stock. Shares reported herein for Capital represent (a) the above-referenced shares of Common Stock issuable upon the conversion of certain Series B Shares and exercised Warrant Shares and as reported for the Fund, for which the LLC serves as the sole general partner, and (b) shares of Common Stock issuable upon the conversion of certain Series B Shares and exercised Warrant Shares held in a separately managed account for which Capital serves as investment adviser. Shares reported herein for Mr. Kolchinsky represent the above-referenced shares of Common Stock issuable upon the conversion of certain Series B Shares and exercised Warrant Shares reported for Capital, for which Mr. Kolchinsky serves as the manager. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

**Item 5. Ownership of Five Percent or Less of a Class:**

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person:**

Not applicable.

CUSIP No. **03211P103**

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:**

Not applicable.

**Item 8. Identification and Classification of Members of the Group:**

Not applicable.

**Item 9. Notice of Dissolution of Group:**

Not applicable.

**Item 10. Certification:**

By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. **03211P103**

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 21, 2014

RA CAPITAL MANAGEMENT, LLC

By: /s/ Peter Kolchinsky

Peter Kolchinsky

Manager

PETER KOLCHINSKY

/s/ Peter Kolchinsky

RA CAPITAL HEALTHCARE FUND, L.P.

By: RA Capital Management, LLC

General Partner

By: /s/ Peter Kolchinsky

Peter Kolchinsky

Manager

Exhibit 1

JOINT FILING AGREEMENT

This Joint Filing Agreement, dated as of March 21, 2014, is by and among RA Capital Management, LLC, Peter Kolchinsky and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Shares, par value \$0.01 per share, of AmpliPhi Biosciences Corporation beneficially owned by them from time to time.

Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

Executed and delivered as of the date first above written.

RA CAPITAL MANAGEMENT, LLC

By: /s/ Peter Kolchinsky

Peter Kolchinsky

Manager

PETER KOLCHINSKY

/s/ Peter Kolchinsky

RA CAPITAL HEALTHCARE FUND, L.P.

By: RA Capital Management, LLC

General Partner

By: /s/ Peter Kolchinsky

Peter Kolchinsky

Manager